2Naravan NA, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results [ J ]. Int J Radiat Oncol Biol Phys, 2006, 64(3): 892- 897.
3Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy [J]. Cancer, 2002, 94(5): 1593-1611.
4Chakravarti A, Berkey B, Robins HI, et al. An update of phase I / II study of gefitinib with radiotherapy in newly diagnosed glioblastoma[J].J Clin Oncol, 2006, 24(18suppl): 1527.
5Brown PD, Krishnan S, Sarkaria JN, et al. Phase I /II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma muhiforme: North Central Cancer Treatment Group Study N0177 [ J ] . J Clin Oneol, 2008,26(34): 5603-5609.
6Tania CR, Javier F, Mauricio C, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor(EGFR) antibody h-R3: Report from a phase I /II trial [ J ] . Cancer Biol Ther, 2006, 5(4): 375-379.
7Stephanie E, Combs MN, Lutz E, et al. Comparative evaluation of radiochemotherapy with temozolomide versus standard-of- care postoperative radiation alone in patients with WHO grade Ⅲ astrocytic tumors [ J ] . Radiother Oncol, 2008, 88(2): 177-182.
8Stupp R, Waren P. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [J].N Engl J Med, 2005, 352(10): 987-996.
9Herrlinger U, Reiger J, Koch D, et al. Phase Ⅱ trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03 [ J ] . J Clin Oncol, 2008, 24(27): 4412-4417.
10Chan ATC, Hsu MM, Goh BC, et al. Muhicenter, phase Ⅱ study of eetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma [ J J . J Clin Oncol, 2005, 23(15): 3568-3576.
